Bosch R J, Griffiths D J, Blom J H, Schroeder F H
Department of Urology, Erasmus University, Rotterdam, The Netherlands.
J Urol. 1989 Jan;141(1):68-72. doi: 10.1016/s0022-5347(17)40591-x.
The possible effect of medical androgen deprivation in the treatment of benign prostatic hyperplasia has been studied in 12 patients. Six patients received the luteinizing hormone-releasing hormone agonist buserelin and 6 others received the antiandrogen cyproterone acetate. The treatment resulted in an average decrease in prostatic size of 29 per cent after 12 weeks as measured by ultrasonography. This decrease led to an increase in peak urinary flow rate, a reduction in residual urine volume and a decrease in daytime voiding frequency. However, it caused no decrease in urethral resistance but only an increase in the bladder contraction strength. After discontinuation of the treatment the prostates showed regrowth to the initial sizes within 6 to 36 weeks. The urodynamic changes were reversed as well. Although statistically significant, the urodynamic changes were minimal from a clinical viewpoint and did not lead to an unobstructed state after 12 weeks of treatment. For this reason the clinical indication for use of medical androgen deprivation in benign prostatic hyperplasia patients will remain limited for the time being.
对12例患者研究了药物性雄激素剥夺疗法治疗良性前列腺增生的可能效果。6例患者接受促黄体生成素释放激素激动剂布舍瑞林治疗，另6例接受抗雄激素药物醋酸环丙孕酮治疗。12周后经超声检查，治疗使前列腺体积平均缩小29%。这种缩小导致最大尿流率增加、残余尿量减少以及白天排尿频率降低。然而，它并未降低尿道阻力，只是增加了膀胱收缩力。治疗中断后，前列腺在6至36周内恢复到初始大小。尿动力学改变也随之逆转。尽管具有统计学意义，但从临床角度来看，尿动力学改变很小，且治疗12周后并未导致通畅状态。因此，目前药物性雄激素剥夺疗法在良性前列腺增生患者中的临床应用指征仍将有限。
